Research analysts at Maxim Group initiated coverage on shares of VolitionRX (NYSEAMERICAN:VNRX) in a report released on Wednesday, MarketBeat.com reports. The brokerage set a “buy” rating and a $6.00 price target on the medical research company’s stock. Maxim Group’s price target suggests a potential upside of 153.16% from the stock’s previous close.
VNRX has been the topic of a number of other research reports. HC Wainwright set a $10.00 price objective on VolitionRX and gave the company a “buy” rating in a research note on Tuesday, February 6th. Benchmark reiterated a “buy” rating and set a $5.00 target price (down from $7.00) on shares of VolitionRX in a research report on Monday.
VolitionRX opened at $2.37 on Wednesday, MarketBeat.com reports. VolitionRX has a fifty-two week low of $2.04 and a fifty-two week high of $2.21.
VolitionRX Company Profile
VolitionRX Limited, a life sciences company, engages in the development of blood tests to help diagnose a range of cancers worldwide. The company develops 39 epigenetic Nu.Q blood assays based on its Nucleosomics biomarker discovery platform. VolitionRX Limited is based in Singapore.
Receive News & Ratings for VolitionRX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VolitionRX and related companies with MarketBeat.com's FREE daily email newsletter.